Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclero
- PDF / 1,018,043 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 60 Downloads / 166 Views
ORIGINAL RESEARCH ARTICLE
Productivity Loss and Associated Costs Among Employed Patients Receiving Disease‑Modifying Treatment for Multiple Sclerosis Machaon Bonafede1 · Rina Mehta2 · Gilwan Kim1 · Ila Sruti1 · Marc Tian2 · Corey Pelletier2 · Neil Goldfarb3 Accepted: 19 September 2020 © The Author(s) 2020
Abstract Objectives The aim of this study was to examine the indirect burden of employed multiple sclerosis (MS) patients initiating disease-modifying therapies (DMTs) in the US. Methods DMT-treated MS patients (DMT users) and direct-matched controls without MS (1:3) were captured using the IBM MarketScan Commercial Claims and Encounters Database and the Health and Productivity Management Database between 1 January 2009 and 1 January 2017. DMT users were also stratified by route of administration. Time loss and costs from absenteeism, short-term disability, and long-term disability were assessed for DMT users and matched controls. Results A total of 3022 DMT users were matched to 9066 controls. Compared with injectable DMT users, oral DMT users took twice as long to initiate therapy but had numerically lower absenteeism costs and significantly lower long-term disability costs in the first year after DMT initiation. The mean (standard deviation) indirect costs of absenteeism, short-term disability, and long-term disability were US$6474 (US$6779), US$2368 (US$5777), and US$280 (US$2578), respectively, for DMT users and US$4468 (US$3814), US$328 (US$1950), and US$36 (US$938), respectively, for controls in the first year (all p
Data Loading...
